Status:
UNKNOWN
Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome
Lead Sponsor:
Nova Mentis Life Science Corp
Collaborating Sponsors:
FourthWall Testing
Conditions:
Autism Spectrum Disorder
Fra(X) Syndrome
Eligibility:
All Genders
6-21 years
Brief Summary
The purpose of this study is to accumulate and quantitatively analyze data on the microbiome, serotonin signaling and genetics, and inflammatory cytokines from patients with Autism Spectrum Disorder a...
Eligibility Criteria
Inclusion
- Early childhood (pre-diagnosis) OR existing ASD diagnosis (Moderate to Severe)
- Existing FXS diagnosis
Exclusion
- Hospitalization
- Enrolled in another clinical study
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04869930
Start Date
November 1 2021
End Date
May 1 2023
Last Update
October 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Broward Health Medical Center
Fort Lauderdale, Florida, United States, 33316